$665.21
2.14% today
Nasdaq, Feb 05, 04:18 pm CET
ISIN
US04016X1019
Symbol
ARGX
Sector
Industry

argenx SE ADR Stock price

$651.30
+5.93 0.92% 1M
+166.78 34.42% 6M
+36.30 5.90% YTD
+247.93 61.46% 1Y
+361.44 124.69% 3Y
+496.24 320.03% 5Y
+628.30 2,731.74% 10Y
Nasdaq, Closing price Tue, Feb 04 2025
-6.26 0.95%
ISIN
US04016X1019
Symbol
ARGX
Sector
Industry

Key metrics

Market capitalization $39.57b
Enterprise Value $36.51b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 22.60
P/S ratio (TTM) P/S ratio 24.50
P/B ratio (TTM) P/B ratio 9.14
Revenue growth (TTM) Revenue growth 101.07%
Revenue (TTM) Revenue $1.61b
EBIT (operating result TTM) EBIT $-396.71m
Free Cash Flow (TTM) Free Cash Flow $-146.69m
EPS (TTM) EPS $-3.50
P/E forward 281.42
P/S forward 18.20
EV/Sales forward 16.79
Short interest 3.26%
Show more

Is argenx SE ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,821 stocks worldwide.

argenx SE ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

33 Analysts have issued a argenx SE ADR forecast:

28x Buy
85%
3x Hold
9%
2x Sell
6%

Analyst Opinions

33 Analysts have issued a argenx SE ADR forecast:

Buy
85%
Hold
9%
Sell
6%

Financial data from argenx SE ADR

Income Statement P&L | Balance Sheet | Cash Flow


TTM Annually
Jun '24
+/-
%
1,615 1,615
101% 101%
100%
- Direct Costs 279 279
62% 62%
17%
1,336 1,336
112% 112%
83%
- Selling and Administrative Expenses 777 777
74% 74%
48%
- Research and Development Expense 843 843
31% 31%
52%
-285 -285
38% 38%
-18%
- Depreciation and Amortization 112 112
6% 6%
7%
EBIT (Operating Income) EBIT -397 -397
30% 30%
-25%
Net Profit -205 -205
49% 49%
-13%

In millions USD.

Don't miss a Thing! We will send you all news about argenx SE ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

argenx SE ADR Stock News

Neutral
GlobeNewsWire
23 days ago
Reported $2.2 billion in preliminary* full-year 2024 global product net sales, inclusive of $737 million in fourth quarter sales
Neutral
GlobeNewsWire
about one month ago
January 6, 2025 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Tim Van Hauwermeiren, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 9:45 a.m. PT.
Neutral
GlobeNewsWire
about one month ago
VYVDURA ® now approved for at-home self-injection in Japan for both generalized myasthenia gravis and CIDP
More argenx SE ADR News

Company Profile

argenx SE is a clinical-stage biotechnology company, which engages in the development of antibody-based therapies for the treatment of autoimmune diseases and cancer. Its products include ARGX-113 for the treatment of autoimmune disease myasthenia gravis and ARGX-110 for the treatment of hematological cancer acute myeloid leukemia. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren on April 25, 2008 and is headquartered in Breda, the Netherlands.

Head office Netherlands
CEO Tim Hauwermeiren
Employees 1,148
Founded 2008
Website www.argen-x.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today